NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch™ eTNS™ System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013. The Monarch eTNS System will be on display at the NeuroSigma Booth #413 throughout the conference.
"This conference represents the first opportunity for Canadian physicians, epilepsy specialists, and healthcare professionals to see the Monarch eTNS system up close, and to learn about the latest results from recent clinical trials. Our team looks forward to forging new relationships with physicians that desire a non-invasive, safe, and affordable neurostimulation therapy for the management of epilepsy and depression," said Leon Ekchian, Ph.D., NeuroSigma's President & CEO.
NeuroSigma will host a Satellite Symposium on the safety and efficacy of eTNS for epilepsy and psychiatric disorders on Tuesday June 25, from 4:30 pm to 6:00 pm in Hall 4, Palais des Congres de Montreal. New results from acute and long-term trials in epilepsy will be presented by Christopher DeGiorgio, M.D., NeuroSigma's Vice President of Neurology and Professor of Neurology at UCLA. These findings will be used to guide NeuroSigma's planned Phase III trial of eTNS for epilepsy. In addition, results from clinical trials of eTNS for major depressive disorder (MDD), attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD) will be presented by Ian Cook, M.D., NeuroSigma's Chief Medical Advisor and Director of the UCLA Depression Research and Clinic Program.
New mindfulness therapy offers hope for teenagers struggling with depression